Technical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
NEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
CLINUVEL Communiqué VI
Melbourne, Australia, 23 December 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Jefferies London Healthcare Conference
CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...
Read More
CLINUVEL Communiqué V
News Communiqué V discusses CLINUVEL's strong financial results in the face of...
Read More
Results of Annual General Meeting 2022
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
CLINUVEL Pharmaceuticals Investor Briefing Melbourne
CLINUVEL held an Investor Briefing in Melbourne, with a presentation by Managing...
Read More
CLINUVEL PHARMACEUTICALS LTD Annual General Meeting - Notice of Meeting & Explanatory Memorandum 2022
CLINUVEL released the formal Notice of Meeting and Explanatory Memorandum for its...
Read More
Strategic Update V
CLINUVEL today announced its fifth Strategic Update, focused on the evolution and...
Read More
H.C. Wainwright 24th Annual Global Investment Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
CLINUVEL Kommuniqué IV
Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...
Read More